Haiyi Deng, Jiating Deng, Xinqing Lin, Wenhui Guan, Ziying Lin, Yanli Qiu, Yilin Yang, Jianhui Wu, Guihuan Qiu, Ni Sun, Maolin Zhou, Jiaxi Deng, Xiaohong Xie, Zhanhong Xie, Ming Liu, Yinyin Qin, Yanbin Zhou, Chengzhi Zhou
BACKGROUND AND OBJECTIVE: Checkpoint inhibitor-related pneumonitis (CIP) is one of the most common serious and fatal adverse events associated with immune checkpoint inhibitors (ICIs). The study sought to identify risk factors of all-grade and severe CIP and to construct a risk-scoring model specifically for severe CIP. METHODS: This observational, retrospective case-control study involved 666 lung cancer patients who received ICIs between April 2018 and March 2021...
April 25, 2023: Clinical Drug Investigation